

1 Omitting re-excision for focally positive margins after breast conserving surgery does not impair
2 disease free and overall survival. Breast Cancer Research and Treatment. Elvira L. Vos, Sabine
3 Siesling, Margreet H.A. Baaijens, Cornelis Verhoef, Agnes Jager, Adri C. Voogd, Linetta B. Koppert.
4 Department of Surgery, Erasmus MC Cancer Institute, PO Box 2400, 3000 CA, Rotterdam, the
5 Netherlands. Email: l.koppert@erasmusmc.nl

6 **Online resource 1**

Table 1 Ipsilateral breast tumor recurrence (IBTR), disease free survival (DFS), and overall survival (OS) rates from Kaplan-Meier analysis and adjusted hazard ratio (HR) from multivariable Cox regression analysis (n = 10,433)

	IBTR Adjusted ^a HR (95%CI)	DFS Adjusted ^a HR (95%CI)	OS Adjusted ^a HR (95%CI)
Resection margins and surgical treatment			
- negative margins and primary BCS only	0.76 (0.43-1.35)	0.81 (0.63-1.04)	1.07 (0.85-1.34)
- focally positive margins			
- primary BCS only	reference	reference	reference
- primary BCS + re-excision	0.30 (0.11-0.82)	0.83 (0.59-1.17)	1.17 (0.87-1.59)
- extensively positive margins and primary BCS + re-excision	0.75 (0.37-1.51)	0.98 (0.73-1.32)	1.22 (0.94-1.59)
Age	0.98 (0.97-1.00)	1.00 (0.99-1.01)	1.05 (1.05-1.06)
Histology			
- ductal	reference	reference	reference
- lobular	0.87 (0.54-1.39)	1.17 (0.98-1.40)	0.93 (0.80-1.08)
- other	0.86 (0.54-1.36)	0.97 (0.80-1.19)	0.94 (0.80-1.11)
Differentiation grade			
- 1	reference	reference	reference
- 2	1.26 (0.84-1.91)	1.59 (1.31-1.92)	1.38 (1.19-1.60)
- 3	2.63 (1.67-4.15)	2.62 (2.13-3.22)	2.02 (1.71-2.37)
- unknown	1.45 (0.78-2.63)	1.50 (1.14-1.97)	1.40 (1.14-1.74)
pT			
- T1	reference	reference	reference
- T2	1.30 (0.95-1.77)	1.60 (1.40-1.82)	1.56 (1.40-1.74)
- T3	1.48 (0.45-4.91)	1.49 (0.94-2.35)	1.89 (1.30-2.75)
- ypT0	-	1.49 (0.47-4.67)	1.54 (0.57-4.15)
pN			
- N0	reference	reference	reference
- N1	1.23 (0.85-1.78)	1.41 (1.20-1.65)	1.37 (1.21-1.57)
- N2	2.32 (1.34-4.01)	3.16 (2.57-3.89)	2.61 (2.18-3.13)
- N3	4.19 (2.15-8.17)	5.51 (4.31-7.06)	4.45 (3.55-5.58)
- unknown	1.11 (0.27-4.54)	1.19 (0.62-2.32)	1.98 (1.34-2.94)
Estrogen receptor			
- positive	reference	reference	reference
- negative	2.32 (1.49-3.59)	1.63 (1.33-2.00)	1.53 (1.26-1.86)
- unknown	2.43 (0.85-6.95)	1.48 (0.96-2.29)	1.12 (0.79-1.60)
Her2Neu receptor			
- negative	reference	reference	reference
- positive	1.10 (0.71-1.72)	0.85 (0.70-1.04)	0.78 (0.64-0.94)
- unknown	0.60 (0.21-1.74)	0.86 (0.55-1.34)	1.04 (0.73-1.50)
Systemic therapy (yes vs no)	0.30 (0.20-0.44)	0.48 (0.41-0.58)	0.81 (0.71-0.93)
Radiotherapy (yes vs no)	0.67 (0.38-1.27)	0.97 (0.76-1.23)	1.11 (0.90-1.36)

^aAdjusted for: age (continuous), histology (ductal, lobular, or other), differentiation grade (1, 2, 3, or unknown), pT stage (1, 2, 3, or ypT0), pN stage (1, 2, 3, or unknown), estrogen receptor status (positive, negative, or unknown), her2neu receptor status (positive, negative, or unknown), use of systemic therapy (any or none), and radiotherapy (yes or no).

1

2

1

Table 2 Ipsilateral breast tumor recurrence (IBTR) rate from Kaplan-Meier analysis and unadjusted hazard ratio (HR) from univariable Cox regression analysis stratified for systemic therapy (chemotherapy and/or hormonal therapy) and according to resection margins after primary BCS and the performance of re-excision in the subcohort (n = 10,433)

	No systemic therapy			Systemic therapy		
	n	5-year	HR (95%CI)	n	5-year	HR (95%CI)
Negative margins and primary BCS only	3214	2.7%	0.87 (0.35-2.14)	4606	2.0%	0.70 (0.34-1.45)
Focally positive margins						
- primary BCS only	183	3.2%	reference	309	2.8%	reference
- primary BCS + re-excision	170	1.9%	0.61 (0.15-2.56)	416	0.8%	0.28 (0.08-1.06)
Extensively positive margins and primary BCS + re-excision	468	4.0%	1.34 (0.49-3.63)	1067	2.3%	0.85 (0.38-1.91)

2